发布求助
文献互助 智能选刊 最新文献

European Journal of Cancer and Clinical Oncology最新文献

筛选
英文 中文
Preclinical evaluation of polymer-bound doxorubicin 聚合物结合阿霉素的临床前评价
European Journal of Cancer and Clinical Oncology Pub Date : 1992-03-01 DOI: 10.1016/0277-5379(91)91369-T
R. Duncan, L. Seymour, K. Ulbrich, F. Spreafico, M. Grandi, M. Ripamonti, M. Farao, A. Suarato
{"title":"Preclinical evaluation of polymer-bound doxorubicin","authors":"R. Duncan, L. Seymour, K. Ulbrich, F. Spreafico, M. Grandi, M. Ripamonti, M. Farao, A. Suarato","doi":"10.1016/0277-5379(91)91369-T","DOIUrl":"https://doi.org/10.1016/0277-5379(91)91369-T","url":null,"abstract":"","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":"42 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"1992-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83488800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 166
Molecular events in B-cell activation and growth: Sensitivity to alpha interferon b细胞活化和生长中的分子事件:对α干扰素的敏感性
European Journal of Cancer and Clinical Oncology Pub Date : 1991-12-01 Epub Date: 2004-04-15 DOI: 10.1016/0277-5379(91)90584-Z
Erik Lundgren , Håkan Hedman , Göran Landberg , Fanyi Chiang, Göran Roos , Rhiannon Sanders
{"title":"Molecular events in B-cell activation and growth: Sensitivity to alpha interferon","authors":"Erik Lundgren , Håkan Hedman , Göran Landberg , Fanyi Chiang, Göran Roos , Rhiannon Sanders","doi":"10.1016/0277-5379(91)90584-Z","DOIUrl":"10.1016/0277-5379(91)90584-Z","url":null,"abstract":"","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":"27 ","pages":"Pages S82-S84"},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90584-Z","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12961549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
A multicentre study of a randomized therapeutic protocol in previously untreated patients with Ph1-positive chronic myelogenous leukaemia: Interferon alfa-2b and hydroxyurea with or without cytosine arabinoside, preliminary results 一项针对未经治疗的ph1阳性慢性髓性白血病患者的随机治疗方案的多中心研究:干扰素α -2b和羟基脲加或不加阿糖胞嘧啶，初步结果
European Journal of Cancer and Clinical Oncology Pub Date : 1991-12-01 Epub Date: 2004-04-15 DOI: 10.1016/0277-5379(91)90561-Q
François Guilhot, Jean-Pierre Lamagnère, Jean Luc Harousseau, Hervé Tilly, Philippe Casassus, Norbert Ifrah, Henri Rochant, Francis Bauters, Gerard Dine, Joseph Tanzer
{"title":"A multicentre study of a randomized therapeutic protocol in previously untreated patients with Ph1-positive chronic myelogenous leukaemia: Interferon alfa-2b and hydroxyurea with or without cytosine arabinoside, preliminary results","authors":"François Guilhot, Jean-Pierre Lamagnère, Jean Luc Harousseau, Hervé Tilly, Philippe Casassus, Norbert Ifrah, Henri Rochant, Francis Bauters, Gerard Dine, Joseph Tanzer","doi":"10.1016/0277-5379(91)90561-Q","DOIUrl":"10.1016/0277-5379(91)90561-Q","url":null,"abstract":"","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":"27 ","pages":"Page S26"},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90561-Q","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12961601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Alpha interferon maintenance therapy in patients with low-grade non-Hodgkin's lymphomas after cytoreductive chemotherapy with prednimustine and mitoxantrone 低级别非霍奇金淋巴瘤患者在prednumstine和mitoxantrone细胞减少性化疗后的α干扰素维持治疗
European Journal of Cancer and Clinical Oncology Pub Date : 1991-12-01 Epub Date: 2004-04-15 DOI: 10.1016/0277-5379(91)90568-X
Wolfgang Hiddemann , Michael Unterhalt , Peter Koch , Martina Nahler , Richard Herrmann , Jürgen van de Loo
{"title":"Alpha interferon maintenance therapy in patients with low-grade non-Hodgkin's lymphomas after cytoreductive chemotherapy with prednimustine and mitoxantrone","authors":"Wolfgang Hiddemann ,&nbsp;Michael Unterhalt ,&nbsp;Peter Koch ,&nbsp;Martina Nahler ,&nbsp;Richard Herrmann ,&nbsp;Jürgen van de Loo","doi":"10.1016/0277-5379(91)90568-X","DOIUrl":"10.1016/0277-5379(91)90568-X","url":null,"abstract":"<div><p>A combination of prednimustine 100 mg/m<sup>2</sup>/day orally, days 1–5, and mitoxantrone 8 mg/m<sup>2</sup>/day intravenously, days 1 and 2, was administered to 19 patients with advanced low-grade non-Hodgkin's lymphoma after failure on or relapse after standard chemotherapy. The prednimustine and mitoxantrone (PmM) regimen was repeated every 4–6 weeks to a maximum of six cycles. Thirteen patients, achieving a complete (4) or partial (9) remission (CR or PR), received two additional courses for consolidation followed by interferon alfa-2b 5 million units (MU) subcutaneously (s.c.) three times weekly until progression or relapse. At the present time, remission duration ranges from 4.5+ to 17.5+ months, with a median of 14.5 months. In a historical comparison to unmaintained first remission preceding the PmM/interferon trial, a tendency towards a longer period of freedom from progression was apparent in the 13 patients receiving interferon maintenance treatment during their second PR or CR. These data provided the basis for a currently ongoing multicentre study randomly comparing initial chemotherapy with PmM versus cyclophosphamide/vincristine (Oncovin)/prednisone (COP) in patients with advanced centroblastic-centrocytic and centrocytic non-Hodgkin's lymphomas, followed by a second randomization in CR and PR patients for maintenance with alpha interferon versus observation only.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":"27 ","pages":"Pages S37-S39"},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90568-X","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12961605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
Role of interferon alfa-2b in the management of patients with advanced cutaneous T-cell lymphoma 干扰素α -2b在晚期皮肤t细胞淋巴瘤患者治疗中的作用
European Journal of Cancer and Clinical Oncology Pub Date : 1991-12-01 Epub Date: 2004-04-15 DOI: 10.1016/0277-5379(91)90569-Y
Tariq I. Mughal
{"title":"Role of interferon alfa-2b in the management of patients with advanced cutaneous T-cell lymphoma","authors":"Tariq I. Mughal","doi":"10.1016/0277-5379(91)90569-Y","DOIUrl":"10.1016/0277-5379(91)90569-Y","url":null,"abstract":"","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":"27 ","pages":"Pages S39-S40"},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90569-Y","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12961606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 9
Interferon and dexamethasone in multiple myeloma patients refractory to chemotherapy 干扰素和地塞米松在化疗难治性多发性骨髓瘤患者中的应用
European Journal of Cancer and Clinical Oncology Pub Date : 1991-12-01 Epub Date: 2004-04-15 DOI: 10.1016/0277-5379(91)90572-U
Jesús F. San Miguel , Maria Moro , Juan Bladé , Luciano Guerras , Jose Hernandez , Ramiro Jimenez-Galindo , Fernando Ortega , Marcos Gonzalez
{"title":"Interferon and dexamethasone in multiple myeloma patients refractory to chemotherapy","authors":"Jesús F. San Miguel ,&nbsp;Maria Moro ,&nbsp;Juan Bladé ,&nbsp;Luciano Guerras ,&nbsp;Jose Hernandez ,&nbsp;Ramiro Jimenez-Galindo ,&nbsp;Fernando Ortega ,&nbsp;Marcos Gonzalez","doi":"10.1016/0277-5379(91)90572-U","DOIUrl":"10.1016/0277-5379(91)90572-U","url":null,"abstract":"","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":"27 ","pages":"Pages S48-S49"},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90572-U","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12961609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Should surgery remain the initial treatment of “operable” breast cancer? 手术是否仍然是“可手术”乳腺癌的初始治疗方法?
European Journal of Cancer and Clinical Oncology Pub Date : 1991-12-01 Epub Date: 2004-04-15 DOI: 10.1016/0277-5379(91)90408-6
John M. Kurtz
{"title":"Should surgery remain the initial treatment of “operable” breast cancer?","authors":"John M. Kurtz","doi":"10.1016/0277-5379(91)90408-6","DOIUrl":"10.1016/0277-5379(91)90408-6","url":null,"abstract":"","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":"27 12","pages":"Pages 1539-1542"},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90408-6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12943908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 11
Prognostic factors in axillary lymph node-negative (pN−) breast carcinomas 腋窝淋巴结阴性(pN−)乳腺癌的预后因素
European Journal of Cancer and Clinical Oncology Pub Date : 1991-12-01 Epub Date: 2004-04-15 DOI: 10.1016/0277-5379(91)90414-9
S. Aaltomaa , P. Lipponen , M. Eskelinen , V.-M. Kosma , S. Marin , E. Alhava , K. Syrjänen
{"title":"Prognostic factors in axillary lymph node-negative (pN−) breast carcinomas","authors":"S. Aaltomaa ,&nbsp;P. Lipponen ,&nbsp;M. Eskelinen ,&nbsp;V.-M. Kosma ,&nbsp;S. Marin ,&nbsp;E. Alhava ,&nbsp;K. Syrjänen","doi":"10.1016/0277-5379(91)90414-9","DOIUrl":"10.1016/0277-5379(91)90414-9","url":null,"abstract":"<div><p>Axillary lymph node-negative (pN−) breast carcinomas (<em>n</em> = 281) were analysed histoquantitatively for two mitotic indexes (MAI, mitotic activity index; M/V, volume corrected mitotic index) and nine nuclear factors with special emphasis on disclosing prognostic factors during a follow-up of 12 years. The M/V index (<em>P</em> = 0.0018), tumour size (<em>P</em> = 0.0052), MAI (<em>P</em> = 0.0115) and histological grade (<em>P</em> = 0.0565) predicted the recurrence-free survival. MAI (<em>P</em> = 0.0007), M/V index (<em>P</em> = 0.0046), tumour size (<em>P</em> = 0.0133), histological grade (<em>P</em> = 0.0528) and S.D. of the nuclear perimetry (<em>P</em> = 0.07) predicted the disease-related survival. In Cox's analysis, MAI (<em>P</em> = 0.004), adjuvant therapy (<em>P</em> = 0.03) and tumour size (<em>P</em> = 0.09) predicted survival independently. Recurrence-free survival was related independently to nuclear perimetry (<em>P</em> &lt; 0.001), SD of nuclear area (<em>P</em> = 0.01) and MAI (<em>P</em> = 0.019) in Cox's analysis. In small (diameter ≤ 20 mm) tumours, S.D. of nuclear perimetry predicted recurrence-free survival (<em>P</em> = 0.03) in Cox's analysis. The results advocate the use of mitotic indexes and nuclear factors in place or in combination with conventional histological grading in predicting the survival and tumour recurrence in axillary lymph node-negative breast carcinomas.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":"27 12","pages":"Pages 1555-1559"},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90414-9","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12943913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 17
Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin A 新型非免疫抑制性环孢素a PSC-833的耐药修饰
European Journal of Cancer and Clinical Oncology Pub Date : 1991-12-01 Epub Date: 2004-04-15 DOI: 10.1016/0277-5379(91)90435-G
Peter R. Twentyman, Norman M. Bleehen
{"title":"Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin A","authors":"Peter R. Twentyman,&nbsp;Norman M. Bleehen","doi":"10.1016/0277-5379(91)90435-G","DOIUrl":"10.1016/0277-5379(91)90435-G","url":null,"abstract":"<div><p>A novel non-immunosuppressive cyclosporin A, PSC-833, has been tested for its ability to circumvent resistance to doxorubicin, vincristine and colchicine in human and murine multidrug resistantant (MDR) cell lines. This compound is shown to be a highly potent resistance modifier, being 7–10-fold more potent than the parent compound, cyclosporin A, whilst approximately equal to cyclosporin A in the growth inhibitory effects of compound alone. Reversal of the P-glycoprotein-associated MDR drug accumulation defect is a major component of resistance reversal for PSC-833, as it is for cyclosporin A.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":"27 12","pages":"Pages 1639-1642"},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90435-G","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12978748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 117
The use of interferon in renal cell carcinoma 干扰素在肾细胞癌中的应用
European Journal of Cancer and Clinical Oncology Pub Date : 1991-12-01 Epub Date: 2004-04-15 DOI: 10.1016/0277-5379(91)90585-2
Hyman B. Muss
{"title":"The use of interferon in renal cell carcinoma","authors":"Hyman B. Muss","doi":"10.1016/0277-5379(91)90585-2","DOIUrl":"10.1016/0277-5379(91)90585-2","url":null,"abstract":"<div><p>Metastatic renal cell carcinoma remains an incurable disease and current modalities can only offer major palliation to a small percentage of patients. Since treatment is palliative, choice and type of therapy must be carefully considered and reconciled with patient desires. When possible, patients should be offered participation in a clinical trial. For patients choosing progestin therapy, treatment with interferon (IFN) or other biological response modifiers can be instituted at the time of progestin failure. Those patients who have slow tumour progression and maintain a high quality of life can be observed without continued progestin therapy. Although pretreatment characteristics predict response to biologicals, no pretreatment characteristic should preclude an individual patient from a trial of IFN therapy. Whether high-dose interleukin-2 (IL-2), IL-2/lymphocyte-activated killer cells, or IL-2/IFN are superior to IFN alone is uncertain, but clinical trials currently underway should help resolve these issues.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":"27 ","pages":"Pages S84-S87"},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90585-2","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12888266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 9
下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信
小红书